[http://dx.doi.org/10.1038/clpt.2014.14](http://dx.doi.org/10.1038/clpt.2014.14)


[http://csdd.tufts.edu/reports/ebooks](http://csdd.tufts.edu/reports/ebooks)


Smed M, Getz KA. Site characteristics influencing the translation of clinical research into clinical practice. *Therapeutic Innovation & Regulatory Science*. 2014; Published online before print March 13, 2014. [RS 3409]  
[http://dx.doi.org/10.1177/2168479014525957](http://dx.doi.org/10.1177/2168479014525957)

**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


Kaitin KI, editor. New breakthrough therapy designation program aims to cut clinical trial time. Tufts Center for the Study of Drug Development Impact Report. 2014 Jan/Feb;16(1)** [RS 3403]


**This publication is for sale at our website  http://csdd.tufts.edu/reports**
http://dx.doi.org/10.1038/clpt.2013.177

http://cognoscenti.wbur.org/2013/12/18/series-prescription-drug-pipeline-sidney-wolfe-kenneth-kaitin


http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/article/articleDetail.jsp?id=828039


http://dx.doi.org/10.1038/clpt.2013.155

http://dx.doi.org/10.1586/17512433.2013.841539

Getz KA. Leveraging pharmacists as a channel to raise clinical research literacy among patient communities. Applied Clinical Trials. 2013;22(10):30-33. [RS 3337]
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Articles/Leveraging-Pharmacists-as-a-Channel-to-Raise-Clini/ArticleStandard/Article/detail/825673

**This publication is for sale at our website  http://csdd.tufts.edu/reports**


http://www.scripintelligence.com/home/Flexible-global-more-adaptive-clinical-trials-2.0-346528


http://dx.doi.org/10.1038/clpt.2013.129


http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Articles/Lifting-Up-a-Fragmented-Study-Conduct-Landscape/ArticleStandard/Article/detail/820680


http://dx.doi.org/10.1517/21678707.2013.819289

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

http://dx.doi.org/10.1038/clpt.2013.117


http://dx.doi.org/10.1177/2168479013494386

Milne CP. On the partnering path from the US to Asia: how far, how fast for university-industry collaborations? *Pharma Focus Asia*. 2013; (18): 40-45. [RS 3323]

http://www.pharmafocusasia.com/strategy/partnering-path-us-asia.htm


http://dx.doi.org/10.1016/j.clinthera.2013.04.004


http://www.panstanford.com/books/9789814316996.html

**This publication is for sale at our website http://csdd.tufts.edu/reports**

http://images2.advanstar.com/PixelMags/pharma-executive/digitaledition/05-2013.html#38


Getz KA. Building clinical trial awareness for patients: why not try the pharmacist? *Pharmaceutical Executive.* Published March 1, 2013 [web document] [RS 3315]

Cohen JP. Think twice about how we let overseas use of Plan B guide us [letter to the editor]. *The Boston Globe.* April 21, 2013: K8. [RS 3314]


Cohen JP, Malins A, Shahpurwala Z. Compared to US practice, evidence-based reviews in Europe appear to lead to lower prices for some drugs. *Health Affairs.* 2013;32:762-770  [RS 3312]
http://content.healthaffairs.org/content/32/4/762.abstract


**This publication is for sale at our website  http://csdd.tufts.edu/reports**
http://www.sciencedirect.com/science/article/pii/S1551714413000153#

http://dij.sagepub.com/content/47/3/336


Getz KA, Stergiopoulos S, Marlborough M, Whitehill J, Curran M, Kaitin, KI. Quantifying the magnitude and cost of collecting extraneous protocol data. *American Journal of Therapeutics*. 2013. [Published Ahead-of-Print; Last Updated: April 9, 2013] [RS 3307]
http://dx.doi.org/10.1097/MJT.0b013e31826fc4aa


http://journals.lww.com/americantherapeutics/Fulltext/2014/01000/Pharmaceutica1_R_D_Performance_by_Firm_Size__6.aspx


Kaitin KI, editor. 89% of trials meet enrollment, but timelines slip, half of sites under-enroll. *Tufts Center for the Study of Drug Development Impact Report*. 2013 Jan/Feb;15(1)** [RS 3302]


**This publication is for sale at our website  http://csdd.tufts.edu/reports**


http://www.annallergy.org/article/S1081-1206(12)00939-8/fulltext

http://dx.doi.org/10.1634/theoncologist.2012-0235


http://link.springer.com/article/10.1007%2Fs12031-012-9803-8

Getz KA, Stergiopoulos S, Kaitin KI. Evaluating the completeness and accuracy of MedWatch data. *American Journal of Therapeutics*. 2012. [Published Ahead-of-Print; Last Updated: January 24, 2013] [RS 3232]
http://dx.doi.org/10.1097/MJT.0b013e318262316f

http://www.topra.org/regulatory-rapporteur-oct-2012


Kaitin KI. Translational research and the evolving landscape for biomedical innovation. *Journal of Investigative Medicine*. 2012;60(7):995-998; doi:10.231/JIM.0b013e318268694f [RS 3228]
http://journals.lww.com/jinvestigativemed/Abstract/2012/10000/Translational_Research_and_the_Evolving_Landscape.5.aspx

http://www.expert-reviews.com/toc/erp/12/3


http://dij.sagepub.com/content/46/5/573


Getz KA. Outsourcing landscape. *Applied Clinical Trials.* 2012;21(5)(suppl):S22-S26 [RS 3217]


http://www.pharmtech.com/pharmtech/article/articleDetail.jsp?id=763940&sk=&date=&&pageID=1

http://jme.bmj.com/content/early/2012/03/01/medethics-2011-100411/reply#medethics_el_3952

http://dx.doi.org/10.1016/j.nbt.2012.02.001

http://www.landesbioscience.com/journals/mabs/article/18812/


Getz KA. Profound changes in the outsourcing landscape. Pharmaceutical Executive. Published February 29, 2012. [web document] [RS 3206]

**This publication is for sale at our website  http://csdd.tufts.edu/reports**
http://dx.doi.org/10.1038/nrd3677

http://dx.doi.org/10.1038/clpt.2011.338


Kaitin KI. Creating innovation nodes to meet unmet medical needs. *Pharmaceutical Technology*. 2011;35(12):27 [RS 3132]

Getz KA. Transforming legacy R&D through open innovation. *ACRP Monitor*. 2011;25(7):17-21 [RS 3131b]


**This publication is for sale at our website** [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)


http://dx.doi.org/10.1038/tpj.2011.63

http://www.sciencedirect.com/science/journal/10983015/14/6

Reichert JM. Therapeutic fc-fusion proteins and peptides as successful alternatives to antibodies. *MAbs*. 2011;3(5):415-416; doi:org/10.4161/mabs.3.5.17334 [RS 3126c]  
http://www.landesbioscience.com/journals/17/article/17334/

http://www.biopharminternational.com/biopharm/Final+Word/The-Case-for-Pediatric-Exclusivity/ArticleStandard/Article/detail/750858

Milne C-P. The case for pediatric exclusivity. *Pharmaceutical Technology*. 2011;35(9):38 [RS 3126]  
http://pharmtech.findpharma.com/pharmtech/Drug+Delivery/The-Case-for-Pediatric-Exclusivity/ArticleStandard/Article/detail/738366

http://www.expert-reviews.com/doi/pdf/10.1586/ecp.11.45


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

http://www.scientificamerican.com/article.cfm?id=a-dearth-of-new-meds&print=true

http://www.landesbioscience.com/journals/mabs/article/16589/


http://appliedclinicaltrialsonline.findpharma.com/appliedclinicaltrials/article/articleDetail.jsp?id=730576

Kaitin KI. 21st Century innovation: academic-industry partnerships are increasingly important in biopharmaceutical innovation. *Pharmaceutical Technology*. 2011;35(6):32 [RS 3119]
http://pharmtech.findpharma.com/pharmtech/article/articleDetail.jsp?id=724982&sk=&date=&pageIndex=1

http://www.emaud.org/Doc/Market_Access_Newsletter_EMAUD_June%202011.pdf


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
Reichert JM. The amazing, multipurpose antibody. *mAbs.* 2011;3(3):221-222. doi:10.4161/mabs.3.3.15625 [RS 3116b]
http://www.landesbioscience.com/journals/17/article/15625/

http://www.futuremedicine.com/action/doSearch?target=article&journal=pme&searchText=cohen+joshua&filter=single&x=25&y=10


http://appliedclinicaltrialsonline.findpharma.com/appliedclinicaltrials/article/articleDetail.jsp?id=719542&sk=9270beba3a37ef7e37f3fa5477ee1cf9%22


Kaitin KI, editor. New or modified indications for existing drugs have steadily increased in the U.S. *Tufts Center for the Study of Drug Development Impact Report.* 2011 Mar/Apr;13(2)** [RS 3111]

http://www.landesbioscience.com/journals/mabs/article/14788/

http://dij.sagepub.com/content/45/2/119.full.pdf+html

Getz KA. Low hanging fruit in the fight against inefficiency. *Applied Clinical Trials.* 2011;20(3):30-32 [RS 3109]

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://www.nature.com/clpt/journal/v89/n2/full/clpt2010286a.html

Stergiopoulos S, Soenen M, Getz KA. Honing reforms from clinical development. Pharmaceutical Executive. Published February 1, 2011 [web document]. [RS 3107]

Getz KA. The ultimate act of appreciation of study volunteers. Focus. 2011;3:8-12 [RS 3106b]

http://www.landesbioscience.com/journals/mabs/article/13895/


http://www.nature.com/nrd/journal/v10/n1/full/nrd3296.html


http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/article/articleDetail.jsp?id=703033&sk=&date=&pageID=2


http://www.landesbioscience.com/journals/mabs/article/13603/

http://www.nature.com/clpt/journal/v88/n5/full/clpt2010167a.html

http://www.nature.com/nbt/journal/v28/n11/full/nbt1110-1160.html

Getz KA. Hurry up and wait, pharma puts the brakes on strategic outsourcing partnering. *Inside Outsourcing*. 2010 Nov;10-16 [RS 3026b]
http://www.nxtbook.com/nxtbooks/advanstar/insideoutsourcing_201011/#/12

http://license.icopyright.net/rights/offer.act?inprocess=t&sid=13&tag=3.7442%3Facx_id%3D693552


Getz KA. Providing results to volunteers. *Applied Clinical Trials*. 2010;19(10):52-59 [RS 3023b]

http://license.icopyright.net/rights/tag.act?tag=3.7442%3Ficx_id=686210


**This publication is for sale at our website** http://csdd.tufts.edu/reports


RS 3016d  Getz KA. Engaging pharmacists in research education. *Applied Clinical Trials*. 2010;19(7)30-32


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0010610


RS 3012  Getz K. FIPNet: Pharma’s new, sexy, but not yet ready for print-time model. *Applied Clinical Trials*. 2009;Suppl:10-12,14,16

Author manuscript; available in PMC 2011 August 4. PMCID: PMC3150117

RS 3010b  Getz KA. Conversations with study volunteers. *Applied Clinical Trials*. 2010;19(5):32-34
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/CRO%2FSponsor/Conversations-With-Study-Volunteers/ArticleStandard/Article/detail/668513


RS 3009  Getz KA. Sizing up the clinical research market. *Applied Clinical Trials*. 2010;19(3):32-34
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/article/articleDetail.jsp?id=660749

RS 3008  Getz KA. With clinical data, less is more. *Applied Clinical Trials*. 2010;19(1):28-30
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/CRO%2FSponsor/With-Clinical-Data-Less-is-More/ArticleStandard/Article/detail/652123

doi:10.1093/protein/gzq018

RS 3007b  Getz KA. Understanding clinical trials: Appreciating medical heroes. *Media Planet*. 2010 Apr

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

http://www.landesbioscience.com/journals/17/article/11320/

http://journals.lww.com/americantherapeutics/Abstract/2010/01000/Private_Sector_Contributions_to_Pharmaceutical.22.aspx


http://www.nature.com/clpt/journal/v87/n3/full/clpt2009293a.html

http://www.nature.com/clpt/journal/v87/n3/full/clpt2009295a.html

http://www.landesbioscience.com/journals/mabs/article/10628/?nocache=503631611

https://www.landesbioscience.com/journals/mabs/article/10786/


**This publication is for sale at our website  http://csdd.tufts.edu/reports**


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


http://www.landesbioscience.com/journals/mabs/article/10059/?nocache=1260067508


RS2921b  Getz KA. Into the aftermath of M&A. *Applied Clinical Trials*. 2009;18(9)  


http://www.es.landesbioscience.com/journals/mabs/article/9675/

http://www.landesbioscience.com/journals/mabs/article/9031/


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


**This publication is for sale at our website  http://csdd.tufts.edu/reports
http://www.landesbioscience.com/journals/17/article/8590/


http://www.pharmexec.com/pharmexec/Sales+Articles/Make-a-Match/ArticleStandard/Article/detail/592061


http://jme.bmj.com/content/35/3.toc


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://www.landesbioscience.com/journals/mabs/article/7946/?nocache=87452482

http://appliedclinicaltrialsonline.findpharma.com/appliedclinicaltrials/article/articleDetail.jsp?id=579328


http://www.merckmanuals.com/home/special_subjects/the_science_of_medicine_and_clinical_trials/the_science_of_medicine.html


http://www.landesbioscience.com/journals/mabs/article/7646/


RS2833b  Getz KA. Should physicians enroll their own patients into clinical trials? *ACRP Monitor.* 2008 Dec;22(7):34-38

**This publication is for sale at our website**  http://csdd.tufts.edu/reports
RS 2833  Kaitin KI. Offshoring cost effective clinical research. *Pharma Focus Asia.* 2008; (9):55-6
http://www.pharmafocusasia.com/clinical_trials/offshoring_cost_effective_clinical_research.htm


RS 2831  Milne C-P Bruss JB. The economics of pediatric formulation development for off-patent drugs. *Clinical Therapeutics.* 2008;30(11):2133-45


http://www.washingtonpost.com/wp-dyn/content/article/2008/09/26/AR2008092603126_pf.html


**This publication is for sale at our website  http://csdd.tufts.edu/reports**
RS 2825b Getz KA. Getting to the heart of public distrust. *Applied Clinical Trials*. 2008;17(9):38-42


http://www.contractpharma.com/articles/2008/06/clinical-research-outsourcing

http://www.manhattan-institute.org/html/mpr_06.htm


**This publication is for sale at our website http://csdd.tufts.edu/reports**


RS 2815 Getz KA. Beyond outsourcing (interview by Jenefer Trevena). *Scrip Supplement Contract Research Update*. 2008;Apr:4:5-6


**This publication is for sale at our website http://csdd.tufts.edu/reports**


Getz KA. In search of informed consent improvement. *Applied Clinical Trials*. 2007;16(11):42-45

DiMasi JA, Grabowski HG. Should the patent system for new medicines be abolished? *Clinical Pharmacology & Therapeutics*. 2007;82(5):488-90

Cohen JP. CEA is not a price control (letter). *Health Affairs*. 2007;26(5):1505

**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


RS 2723  Getz KA. Global clinical trials activity in the details. *Applied Clinical Trials.* 2007;16(9):42-44  


RS 2721  Kaitin KI, editor. Despite more cancer drugs in R&D, overall U.S. approval rate is 8%. *Tufts Center for the Study of Drug Development Impact Report.* 2007 Sep/Oct;9(5)**

http://www.springerlink.com/content/f03333rv1823w611/fulltext.pdf


RS 2717  Getz KA. CRA: jack of all trades. *Applied Clinical Trials.* 2007;16(7):36-38  
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=439804


**This publication is for sale at our website  http://csdd.tufts.edu/reports**

RS 2714  Getz KA. CRO shifts in the outsourcing market. *Applied Clinical Trials.* 2007;16(5):35-38  
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=424918


http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=416536

RS 2710  Getz KA, Sergeant E, Kremidas J. Mission possible: rebranding clinical research. *Applied Clinical Trials.* 2007;16(4):35-6,8  
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=416537

http://www.jstor.org/pss/30033224

RS 2708  Getz K, Wenger J. High times for the CRO heavyweights. *Scrip supplements.* 2007 Mar;5-6  


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
RS 2704  Getz KA. Drowning in the sea of regulatory compliance. *Applied Clinical Trials*. 2007;16(2):32-34
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=401621


http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=392454

http://classic.the-scientist.com/2006/12/1/49/1/

RS 2624b  Cohen J  Cairns C  Paquette C  Faden L. Comparing patient access to pharmaceuticals in the UK and US. *Applied Health Economics and Health Policy*. 2006;5(3):177-87


http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=382875


**This publication is for sale at our website  http://csdd.tufts.edu/reports**


RS 2616  Kaitin KI, editor. Number of vaccines entering clinical study rose only modestly since 1990s. Tufts Center for the Study of Drug Development Impact Report. 2006 Jul/Aug;8(4)**


**This publication is for sale at our website  http://csdd.tufts.edu/reports


RS 2606  Getz KA. Forgotten voices in the transparency debate: online trial registries alone will not succeed at rebuilding public confidence. *Applied Clinical Trials*. 2006;15(4):42-44
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=316473


http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=282477

RS 2601  Getz KA. The imperative to support site adoption of EDC. *Applied Clinical Trials*. 2006;15(1):38-40
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=283027


**This publication is for sale at our website  http://csdd.tufts.edu/reports
   http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=261633

RS 2517 Getz KA. Have we pushed our PIs too far? *Applied Clinical Trials.* 2005;14(9):34-36
   http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=176904&&pageID=1

   http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=172272

RS 2515 Milne C-P Kaitin KI. Down the critical path: who should lead? *Applied Clinical Trials.* 2005;14(8):56
   http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=172279


RS 2512 DiMasi JA Hansen RW Grabowski HG. Reply: setting the record straight on setting the record straight: response to the Light and Warburton rejoinder. *Journal of Health Economics* 2005 Sep;24(5):1049-53


RS 2510 Kaitin KI, editor. Longer clinical times are extending time to market for new drugs in U.S. *Tufts Center for the Study of Drug Development Impact Report.* 2005 Nov/Dec;7(6)**

RS 2509 Reichert JM Rosensweig CJ Faden LB Dewitz MC. Monoclonal antibody successes in the clinic. *Nature Biotechnology* 2005;23(9):1073-8


**This publication is for sale at our website  http://csdd.tufts.edu/reports**
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>RS 2423</td>
<td>Milne C-P. Harbingers, or harvesters of change? <em>European Pharmaceutical Review Supplement (Outsourcing)</em>. 2004 Winter:12-17</td>
</tr>
</tbody>
</table>

**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=12516


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


RS 2312 Kaitin KI, editor. Switching drugs from prescription to OTC status on rise in U.S. and EU. *Tufts Center for the Study of Drug Development Impact Report.* 2003 Sep/Oct;5(5)**


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


Kaitin KI, editor. Increased pressure on drug industry is leading to greater focus on Japan. *Tufts Center for the Study of Drug Development Impact Report*. 2003 Jan/Feb;5(1)**


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
Kaitin KI, editor. Approval times for new drugs fell by more than a year during PDUFA. *Tufts Center for the Study of Drug Development Impact Report.* 2002 Nov/Dec;4(6)**


http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=36729


http://www.nature.com/nbt/journal/v20/n7/abs/nbt0702-659.html

Cohen J Chee J. Pharmacy benefit managers’ role in facilitating Medicare beneficiary access to pharmaceutical care. *Disease Management & Health Outcomes.* 2002;10(4):221-7


**This publication is for sale at our website  http://csdd.tufts.edu/reports**


RS 2203  Reichert JM Therapeutic monoclonal antibodies: trends in development and approval in the US. *Current Opinion in Molecular Therapeutics.* 2002;4(2):110-8


RS 2123  Kaitin KI. El papel de la investigación básica. [editorial]. (Original title: The quest for cures -- the role of the research-based drug industry) *La Vanguardia* (Barcelona). 2001 18 Mar*


**This publication is for sale at our website  http://csdd.tufts.edu/reports**


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


Kaitin KI, editor. FDA’s fast track program results in 62% approval rate after first 3 years. Tufts Center for the Study of Drug Development Impact Report. 2001 Jan/Feb;3(1)**


**This publication is for sale at our website http://csdd.tufts.edu/reports
Cross-functional team focus on marketing is key to project success. *Tufts Center for the Study of Drug Development Impact Report.* 2000 Dec;2(9)


Kaitin KI. Don’t turn back the clock on drug regulatory reform. *Tufts Center for the Study of Drug Development Impact Editorial.* 2000 Sep;2(7)  
[http://journals.lww.com/oncology-times/Fulltext/2001/03000/Don_t_Turn_Back_the_Clock_on_Drug_Regulatory.4.aspx](http://journals.lww.com/oncology-times/Fulltext/2001/03000/Don_t_Turn_Back_the_Clock_on_Drug_Regulatory.4.aspx)


[http://www.acnp.org/g4/GN401000182/Default.htm](http://www.acnp.org/g4/GN401000182/Default.htm)

**This publication is for sale at our website**  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)


RS 2008  Drug firms embrace pediatric study program during first 2 years of FDAMA.  *Tufts Center for the Study of Drug Development Impact Report*. 2000 Apr;2(3)


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


RS 9912  Planning, independence, feedback keep global R&D projects on track.  *Tufts Center for the Study of Drug Development Impact Report*. 1999 Sep;1(3)


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


RS 9810  Lasagna L.  Presentation of the Louis Lasagna Chair of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine.  *Journal of Clinical Pharmacology*. 1998;38:570-1, 575-6


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


RS 9725  Lasagna L Weintraub M, editors. *Year book of drug therapy 1997.* St. Louis: Mosby;1997*


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


RS 9715 Kaitin KI. FDA reform: setting the stage for efforts to reform the agency. *Drug Information Journal.* 1997;31(1):27-33

RS 9714 Lasagna L DiMasi JA. Let’s speed up the approval of new indications for old drugs. *Medical Marketing & Media* 1996;31(12):88-9

http://www.nature.com/clpt/journal/v60/n6/abs/clpt1996527a.html


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
RS 9625  DiMasi JA.  *Written testimony*.  House Subcommittee on Human Resources and Intergovernmental Affairs, Committee on Government Reform and Oversight, U.S. House of Representatives.  September 12, 1996


RS 9623  Kaitin KI.  *Statement*.  Hearing before the Subcommittee on Health and Environment of the Committee on Commerce, House of Representatives.  The Need for FDA Reform, February 27, 1996.  104th Congress 2d Session:81-7, 100-1


**This publication is for sale at our website  http://csdd.tufts.edu/reports**


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

RS 9506  Shulman SR  Seibring M  Manocchia M.  *Letter to Hon. Judd Gregg, U.S. Senate.* Hearing before the Subcommittee on Aging of the Committee on Labor and Human Resources, United States Senate, July 13, 1995 104th Congress 1st Session:47-8


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

Brown JS DiMasi JA Gosse ME Manocchia M Kaitin KI Shulman SR. Incentives for the development of drugs for AIDS and other life-threatening illnesses: points to consider. For the Public/Private Issues and Development Subcommittees of the National Task Force on AIDS Drug Development meeting, April 25, 1995


Bloom BR. The United States needs a national vaccine authority. Science 1994 Sep 2;265(5177):1378-80


***This publication is for sale at our website http://csdd.tufts.edu/reports***


Inman WHW. Drug Safety Research Unit, University of Southampton. PEM News. 1993 Nov; (8).


**This publication is for sale at our website http://csdd.tufts.edu/reports**


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

RS 9273  *The Development and Use of Antiprogestin Drugs: Social, Political, Economic and Legal Issues, Medicine in the Public Interest Conference, February 6-7, 1992.*  Boston;MIPI:1992


RS 9266  Scoville B.  Shifting the burden: restructuring the drug review process.  *Journal of Clinical Pharmacology and Therapeutics.* 1991;49(3):229-33


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


Fernandez-Carol CM Kaitin KI. The generic scandal and FDA reforms. Pharmaceutical Medicine. 1991;5:13-17

Inman WHW. Drug Safety Research Unit, University of Southampton. PEM News. 1991 Aug;(7)


DiMasi JA Lasagna L. Development of supplemental indications for already-approved drugs by the United States pharmaceutical industry. Journal of Clinical Research and Pharmacoepidemiology.1991;5:19-33


**This publication is for sale at our website http://csdd.tufts.edu/reports**

RS 9054  Shulman SR.  La legislazione sulla responsabilità di produzione.  *Informazioni Stampa Interesse Sanitario* (Rome) 1990 Apr 9;#15:27-8

RS 9053  Lasagna L.  Le attività del Centro per lo Studio dello Sviluppo dei Farmaci.  *Informazioni Stampa Interesse Sanitario* (Rome) 1990 Apr 9;#15:26

RS 9052  Inman WHW.  Drug Safety Research Unit, University of Southhampton, *PEM News*. 1988 Sep(5)


RS 9048  Shulman SR  Raiford DS.  FDA regulations provide broader access to unapproved drugs.  *Journal of Clinical Pharmacology*.1990;30:585-7


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
| RS 8934 | Grabowski HG. Medicaid patients' access to new drugs. *Health Affairs* 1989;7:102-14 |

**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
| RS 8930 | Inman WHW. Drug Safety Research Unit, University of Southampton. *PEM News*. 1988 Sep;(5) |
| RS 8830 | Shulman SR. Drug refusal policy must include legal definition of competence. *Hospital Formulary*. 1988 Jan;23:79 |
| RS 8829 | DiMasi JA. The notion of "acceptable risk": comment. *Journal of Clinical Epidemiology*. 1988;41(9):939-41 |

**This publication is for sale at our website**  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


RS 8710  Inman WHW.  Drug Safety Research Unit, University of Southampton, *PEM News.* 1987 Mar;(4)


RS 8705  Kaitin KI.  Impact of generic drugs on the pharmaceutical marketplace. *Private Practice.* 1986 Sep;18:18-20  (Originally appeared as "Generic firms shun research, share rewards.")


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


RS 8600  Berry CL.  Unprovable verities.  *Human Toxicology.* 1985;5(3):159-60

RS 8699  Weintraub M  Northington F.  Drugs that wouldn't die.  *Journal of the American Medical Association.*  1986 May 2;255(17):2327-8


RS 8696  Inman WHW.  Drug Surveillance Research Unit, University of Southampton.  *PEM News.* 1985 Dec;(3)

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

RS 8694  Kitch E.  Vaccines and product liability: a case of contagious litigation.  Regulation.  1985 May/Jun


RS 8691  Walker SR  Schultz E  Schuppan D  Gelzer J.  A comparative retrospective analysis of data for short- and long-term animal toxicity studies on 40 pharmaceutical compounds.  Archives of Toxicology.  1984;7:485-7


RS 8591  Mattison N.  Sources of change affecting the U.S. pharmaceutical industry in the 1980s.  Pharmaceutical Medicine.  1985;1:13-6*


**This publication is for sale at our website  http://csdd.tufts.edu/reports**


Lasagna L. *Impediments to Vaccine Research, Medicine in the Public Interest Conference, Jan 9-10, 1984*. Boston: MIPI;1984

Inman WHW. Drug Surveillance Research Unit, University of Southampton, *PEM News*. 1984 Aug;(2)


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
RS 8474b  Bakke OM.  Drug selection in a regulated society: the Norwegian experience.  
*Hospital Formulary.* 1984 May;19:411-2,5,8,21

RS 8474  Weintraub M.  P&T committees and drug regulation in Norway: lessons to be 
learned.  *Hospital Formulary.* 1984;19:347

RS 8473  Weintraub M.  Ethical concerns and guidelines in research in geriatric 
pharmacology and therapeutics: individualization, not codification.  *Journal of the 
American Geriatrics Society.* 1984;32(1):44-8

RS 8472  Herman SS.  The noninstitutional review board: a case history.  *IRB: A Review of 

PS 8471  Freedman DX.  When does a new drug become old?  Remarks presented at the 
Food and Drug Law Institute's 27th Annual Education Conference, Dec 13, 1983

RS 8470  Lavori PW  Louis TA  Bailar JC III  Polansky M.  Designs for 
experiments--parallel comparisons of treatment.  *New England Journal of 
Medicine.* 1983;309(21):1291-9

RS 8469  Vane JR.  Wellcome relief: new drugs for the Third World.  *The Health Sciences.*  
1982 Oct 15

RS 8468  Hutt PB.  The importance of patent term restoration to pharmaceutical innovation: 
will extending patent life increase drug innovation?  A search for answers.  *Health 
Affairs.* 1982;1(2):5-24

RS 8374  Lasagna L.  Generic drugs and the elderly.  *Journal of the American Geriatrics 
Society.* 1983;31(9):571-2

1983;11(11):63-7

RS 8372  Lasagna L.  How much regulation is desirable in industry?  In: *Regulation and 
restraint in contemporary medicine in the UK and the USA.*  L'Etang H, editor. 

RS 8371  Wardell WM.  Regulation of the discovery, development, and supply of new 
drugs: lessons for medicine.  In: *Regulation and restraint in contemporary 
medicine in the UK and the USA.*  L'Etang H, editor.  London: The Royal Society 
of Medicine and MacMillan, 1983:3-12

RS 8370  Wardell WM.  The role of regulators.  In: *The second pharmacologic revolution.* 
Wells N, editor.  London: Office of Health Economics; 1983:105-9*

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


RS 8367  Superior Court of New Jersey, Appellate Division. Carol Ann Feldman, an infant, by her parent and guardian *ad litem* Harold Feldman, Plaintiffs - Appellants vs. Lederle Laboratories, a corporation, and American Cyanamid Co., a corporation, Defendants - Respondents. Nov 1983

RS 8366  Inman WHW. Drug Surveillance Research Unit, University of Southampton. *PEM News*. 1983 Aug;(1)

RS 8365  Covington TR. Toward a rational approach to the issue of prescribing authority for pharmacists. *Drug Intelligence and Clinical Pharmacy*. 1983;17(9):660-6


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
RS 8359  Diggle GE  Griffin JP.  Licensing times in granting marketing authorizations for medicines--a comparison between the U.K. and U.S.A.  Pharmacy International. 1982;3(7):230-6


RS 8358b  Zbinden G  Flury-Roversi M.  Significance of the LD 50 test for the toxicological evaluation of chemical substances.  Archives of Toxicology. 1981 Apr;47(2):77-99


RS 8357b  Mahler H.  Essential drugs for all.  Papers presented at the Eleventh IFPMA Assembly, Washington DC, Jun 7-8, 1982:64-70


RS 8262  Wardell WM.  Is pharmaceutical innovation declining?  Pharmaceutical Technology. 1982 Sep


RS 8260  Wardell WM  Mattison N.  The assessment of medical technologies using risk-benefit, cost-benefit, and cost-effectiveness analysis.  In: WMA Follow-up Committee on Development and Allocation of Medical Care Resources.  Tokyo: Japan Medical Association;1982;84-98*

**This publication is for sale at our website  http://csdd.tufts.edu/reports**


Schweiker RS. Remarks by the Honorable Richard S. Schweiker to the National Pharmaceutical Council Symposium. June 23, 1982


Shubin S. The MAC program and advisors to the government. *Hospital Formulary* 1981 Aug;16(8):869-79


Wardell WM. A statement on pharmaceutical patent life and innovation. Submitted to the Subcommittee on Investigations and Oversight of the Committee on Science and Technology, U.S. House of Representatives. Feb 4, 1982


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


RS 8153  Wardell WM  Velo GP, editors.  *Drug development, regulatory assessment, and postmarketing surveillance.*  NATO Advanced Institutes Series, 39 (Series A: Life Sciences) New York: Plenum; 1981*


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


Hansen RW. Effects of incremental costs on pharmaceutical innovation. (Working Paper Series No. GPB-81-2) Rochester NY: Graduate School of Management, University of Rochester, Dec 1980

Hansen RW. The cost of regulation in the pharmaceutical industry: economic implications of three recent studies. (Working Paper Series No. PS 81-2) Rochester NY: Graduate School of Management, University of Rochester, Dec 1980

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
RS 8057  Wardell WM. Therapeutic drugs as an example of the regulation of health care: efficient and inefficient ways of utilizing resources. In: Proceeding of the World Medical Association Follow-Up Committee Meeting on Development and Allocation of Medical Care Resources. Tokyo: Japan Medical Association, 1980:139-50*

RS 8056  Wardell WM. Drug therapy (a response to questions on specific aspects of drug regulation). Private Practice. 1980 Oct:24-31*


RS 8051  Lasagna L. Pharmacology's labs have moved faster than the regulators. Medical Tribune. 1980 May 7;21:17


RS 8046  Hansen RW. Pharmaceutical development costs by therapeutic categories. (Working Paper Series No. GPB-80-6) Rochester, NY: Graduate School of Management, University of Rochester; Mar 1980*

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


RS 8039  Letters to the editor. in re: the drug lag.  Regulation. 1980 Mar/Apr;4(2):59-60


**This publication is for sale at our website  http://csdd.tufts.edu/reports**

Merrill RA. Problems involving federal conflict of interest restrictions on members of FDA advisory committees and agency officials. Rochester, NY: Center for the Study of Drug Development; Apr 1980


**This publication is for sale at our website http://csdd.tufts.edu/reports


RS 7939  Lasagna L. Toxicological barriers to providing better drugs. *Archives of Toxicology.* 1979;43(1):27-33


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


RS 7926b  Lasagna L. The diseases and drug needs of the Third World. *Journal of Chronic Diseases*. 1979;32(6):413-4


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


Wardell WM. A close inspection of the 'calm look': rhetorical amblyopia and selective amnesia at the FDA. *Journal of the American Medical Association.* 1978;239(19):2004-11


Landau RL. *What you should know about estrogens, or the perils of Pauline.* Rochester, NY: Center for the Study of Drug Development; Jun 1978

**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


**This publication is for sale at our website  http://csdd.tufts.edu/reports**


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


**This publication is for sale at our website  http://csdd.tufts.edu/reports**